# TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients

> **NCT01202825** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 72 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** TMC647055
- **DRUG:** Placebo
- **DRUG:** TMC647055
- **DRUG:** TMC647055
- **DRUG:** Placebo
- **DRUG:** TMC435
- **DRUG:** Placebo
- **DRUG:** TMC647055
- **DRUG:** Placebo
- **DRUG:** TMC647055

## Key facts

- **NCT ID:** NCT01202825
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01202825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01202825, "TMC647055HPC1001 - First-in-human Trial to Examine Safety, Tolerability and Pharmacokinetics (How the Drug is Absorbed Into the Bloodstream) of Increasing Single Oral Doses and of Increasing Repeated Oral Doses of TMC647055 in Healthy Volunteers and in Hepatitis C Virus Infected Patients". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01202825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*